标题
Amyloid-Related Imaging Abnormalities and β-Amyloid–Targeting Antibodies
作者
关键词
-
出版物
JAMA Neurology
Volume -, Issue -, Pages -
出版商
American Medical Association (AMA)
发表日期
2022-02-01
DOI
10.1001/jamaneurol.2021.5205
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Donanemab in Early Alzheimer’s Disease
- (2021) Mark A. Mintun et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
- (2021) Chad J. Swanson et al. Alzheimers Research & Therapy
- PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
- (2021) Stephen Salloway et al. NATURE MEDICINE
- Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks
- (2020) Heather Guthrie et al. JOURNAL OF ALZHEIMERS DISEASE
- Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
- (2020) Martin Tolar et al. Alzheimers Research & Therapy
- Calibration of a simplified ARIA‐E MRI severity scale suitable for clinical practice
- (2020) Gregory Klein et al. Alzheimers & Dementia
- Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
- (2019) Gregory Klein et al. Alzheimers Research & Therapy
- Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise
- (2018) Christopher H. van Dyck BIOLOGICAL PSYCHIATRY
- Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study
- (2018) Stephen P. Salloway et al. JOURNAL OF ALZHEIMERS DISEASE
- Costs and Burden Associated With Loss of Labor Productivity in Informal Caregivers of People With Dementia
- (2018) Marta Farré et al. JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
- Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab
- (2018) Enchi Liu et al. NEUROLOGY
- ABBY
- (2018) Jeffrey L. Cummings et al. NEUROLOGY
- Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
- (2018) Lawrence S. Honig et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies
- (2018) H. Robert Brashear et al. JOURNAL OF ALZHEIMERS DISEASE
- The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer’s patients: An interobserver study
- (2017) Roland M. Martens et al. EUROPEAN RADIOLOGY
- Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer’s Disease Patients
- (2017) Nzeera Ketter et al. JOURNAL OF ALZHEIMERS DISEASE
- Unknown
- (2017) JOURNAL OF NEUROIMAGING
- Alzheimer’s disease prevention: from risk factors to early intervention
- (2017) Marta Crous-Bou et al. Alzheimers Research & Therapy
- A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
- (2017) Susanne Ostrowitzki et al. Alzheimers Research & Therapy
- A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer’s disease
- (2016) Mark Brody et al. JOURNAL OF ALZHEIMERS DISEASE
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
- (2016) Jeff Sevigny et al. NATURE
- Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies
- (2016) Adrian Ivanoiu et al. Alzheimers Research & Therapy
- First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease
- (2016) Marielle Delnomdedieu et al. Alzheimers Research & Therapy
- Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
- (2016) Rik Vandenberghe et al. Alzheimers Research & Therapy
- Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
- (2014) Stephen Salloway et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
- (2014) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- An MRI Rating Scale for Amyloid-Related Imaging Abnormalities with Edema or Effusion
- (2013) F. Barkhof et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- MR Imaging Features of Amyloid-Related Imaging Abnormalities
- (2013) J. Barakos et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis
- (2012) Reisa Sperling et al. LANCET NEUROLOGY
- Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer’s disease study cohorts from phase 3 trials of semagacestat and solanezumab
- (2011) Christopher Carlson et al. Alzheimers & Dementia
- Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
- (2011) Reisa A. Sperling et al. Alzheimers & Dementia
- Amyloid load in nondemented brains correlates with APOE e4
- (2010) Richard J. Caselli et al. NEUROSCIENCE LETTERS
- The Microbleed Anatomical Rating Scale (MARS): Reliability of a tool to map brain microbleeds
- (2009) S. M. Gregoire et al. NEUROLOGY
- A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
- (2009) S. Salloway et al. NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search